Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.
FDA back in business after 2016's fall in drug approvals.